logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Pharmaceutical companies, managers, healthcare professionals and researchers seek to strengthen the excellence of clinical trials in Spain

Farmaindustria brings together in Madrid more than 120 experts to continue advancing in an area in which our country is already an international benchmark

Source: www.farmaindustria.es

What are the criteria that the centers must meet to host clinical trials; how to improve its management or how to facilitate patient participation. Some of the questions that have been asked by more than 120 health professionals, researchers and managers of hospitals and public and private centers that have participated this Thursday in Madrid, together with representatives of pharmaceutical companies that promote trials, in a work meeting organized by Farmaindustria to advance the excellence of clinical research in Spain, the phase of development that serves to demonstrate the efficacy and safety of new medicines.

The general deputy director of Farmaindustria, Javier Urzay, explained how the conduct of clinical trials in Spanish hospitals and research centers has very positive consequences for the health system and the centers themselves, because the trials attract economic investments; for health professionals, because they add reputation and experience to complement their care work with the researcher, and for the pharmaceutical industry, because they can count on health professionals and adequate clinical facilities to boost their research and development of new medicines.

But, above all, clinical trials are beneficial for patients, who, thanks to them, can have early access to the most innovative treatments, not yet authorized, which in certain pathologies and when other treatments have failed can mean survival itself .

The objective of the forum is to continue moving forward in a way in which Spain is already an international benchmark, thanks to the commitment of pharmaceutical companies and collaboration with health administration, hospitals, health professionals and patients. Spain already participates in three out of ten trials carried out in Europe, and has positioned itself very well particularly in the early stages, the most complex of the trials. It is important to continue working to take advantage of these strengths and to become a leading country in clinical research.

In this line, the meeting discussed the latest data and future prospects of the BEST Project of excellence in clinical research, promoted by Farmaindustria to promote trials in Spain, as well as areas for improvement in the field of patient recruitment, one of the aspects where there is a greater capacity for progression in Spain. In its twelve years of life, the BEST Project has facilitated the completion of more than 3,000 trials, involving 150,000 patients.

The participants also had access to updated information on good practices in talent management in research teams and in the management of clinical trials in the hospital pharmacy. Other key aspects addressed were the attraction of trials in early phases, the digitalization of processes, innovation in the R & D of new medicines or the criteria of competitiveness and measurement of results.

As a result of this workshop, a consensus document with criteria and priorities will soon be drawn up to boost Spain’s competitiveness as a world reference for clinical research.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.